Evidence map›Paper›PMID 42317255›Full record

ArticleTherapeutic advances in medical oncology2026

Response to nivolumab as an immune checkpoint inhibitor rechallenge for esophageal squamous cell carcinoma with

Hiroyuki Kodama, Toshiki Masuishi, Yasunobu Ishizuka, Tomoki Sakakida, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Waki Hosoda and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hiroyuki KodamaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0009-0003-4548-4109
Toshiki MasuishiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan.ORCID https://orcid.org/0000-0002-7521-1596
Yasunobu IshizukaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0009-0003-3305-4013
Tomoki SakakidaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Kazunori HondaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0001-5090-9771
Yukiya NaritaDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0002-8018-0077
Hiroya TaniguchiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0003-1407-6682
Shigenori KadowakiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.ORCID https://orcid.org/0000-0001-9923-5309
Masashi AndoDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Waki HosodaDepartment of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The

Indexed as

esophageal squamous cell carcinomanivolumabprogrammed death-ligand 1 (PD-L1) amplification

Identifiers

PMID42317255
PMCPMC13272978

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.